Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

December 12, 2024

Araque et al. • 2024 • WCIRDC

Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST

December 12, 2024

Fonseca et al. • 2024 • WCIRDC

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis

November 25, 2024

Badiu et al. • 2024 • AACE MENA 2024 Congress

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

June 7, 2024

Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.

Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)

June 3, 2024

2024 • ENDO 2024